2025 Q3 -tulosraportti
64 päivää sitten42 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
272 586
Myynti
Määrä
162 534
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 19 948 | - | - | ||
| 2 500 | - | - | ||
| 1 687 | - | - | ||
| 10 889 | - | - | ||
| 6 079 | - | - |
Ylin
0,218VWAP
Alin
0,2VaihtoMäärä
1,3 6 527 294
VWAP
Ylin
0,218Alin
0,2VaihtoMäärä
1,3 6 527 294
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 6 527 294 | 6 527 294 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 6 527 294 | 6 527 294 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 24.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 26.11.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 14.5.2025 | |
| 2024 Q4 -tulosraportti | 25.2.2025 | |
| 2024 Q3 -tulosraportti | 27.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenIf you are interested in this stock, then watch the interview with Jeff https://www.youtube.com/watch?v=BI2P6nBNMvw&t=740s Anyway, I am strengthened in that this is a mkt interesting case/stock, it feels like one is really on the way to succeed and if one gets the reinbursement during the year according to plan, then I believe that brilliant times await. I bought a bit more
·12 t sitten · MuokattuIt's difficult to read Jeff then. But, if one believes him, then it is very positive. Otherwise, there's little new, but he somehow promises something for the annual report. Even if it's only an update on how things are going by the annual report possibly. So that's what people are waiting for. So each and every one of us must interpret how positive this is based on what Jeff shared at the meeting with shareholders. It's probably natural that one doesn't talk about any potential dialogues with partner candidates, if they should have started, or will develop during February. The natural thing is to wait a bit and say it when an agreement is in place. I believe at least things usually work like that in such processes. Also, one should not forget the medicare application in a few months. Maybe that makes partners even more willing?- ·2 päivää sitten · Muokattuhttps://www.youtube.com/watch?v=BI2P6nBNMvw&t=740s It can be seen as just an opinion. But this is probably the first time I really hear Jeff Boercherdinger say that the test is almost "guaranteed" to provide good enough accuracy. "Proven to be accurate" are the words he uses. "Limited risk around the product" and "very enthusiastic response to the launch". "adopted in Numerous centers already". "I wish to share more information about that in February, when we announce the full year 2025 results" He still maintains that they will apply for Medicare in mid-2026, no change on that point. I am left with the impression from question 1: that Jeff describes medicaid as a poor man's thing without putting that label on it, and that it is medicare that means the most for Immunovia (is that the insured then) !? So he thinks that medicaid, which will take years anyway, has little significance. Question 2 about "investment sentiment picking up": Yes "mood is improving", Acquisitions are somewhat new in the sector and more common in pharma, but it is a signal that can lead to further acquisitions. You haven't seen as many acquisitions in the diagnostics sector, but when it opens up a bit, more interest in Immunovia among investors can be seen. Question 3 about "tariffs": Minimal impact. Small ingredient productions in countries like Germany. Question 4 about whether the California news will provide the first commercial revenues already for Q1 2026: Expects that multiple centers will sign up to use the test. Usual sequence for how things tend to settle: Enter into an agreement with the center, a period of time where they implement the test, and start using it. Then you start to see volume increase. Regarding the revenue part, it will depend on the invoicing we do at the beginning of this year. They start early with invoicing to see if they can get some "reimbursements before we have formal coverage decisions". So he thinks we have to wait and see "how things play out". And that it will have an impact for California as well, as in other states. Question 5 about reverse split of the stock. If the board and larger shareholders now see significant potential for share price increases now that you are on the verge of commercial rollout in the USA? Answer: RS was concluded. Timing signals from shareholders. Bullish on Immunovia, much value in the company. This is poorly reflected in the share price and "in the market capatilization of the company. When you look at the fact that this is a large market with a big unmet need. We have an excisting product. We have had good clinical results behind it and we are getting good feedback from the market. So we do um we do see good opportunity going forward. Slightly unfortunate closing of his eyes when he said the last sentence about "good opportunity" (body language). One might perhaps think that he is sad about what is happening on the streets with the ICE bullies, or? Wouldn't surprise me..
- ·3 päivää sitten · MuokattuI myself believe there is money in a cancer blood test. But today's government in the USA is "very special". So there are probably other markets in the world, one would think? But that happens only after the USA? And there is a certain burn rate now, and how will that go then? https://forum.placera.se/bolag/immunovia Now she is posting extra actively again. At least be a little aware that Elvira on the Placera forum was one of several who hyped the stock between the emission in May 2025 and the next emission autumn 2025. It could be pure naivety. But I myself have lost money on that crowd who go on like that talking about partnerships in the east and in the west. But of course, one day a partnership might come. But no one knows when. One might get news about negotiations, for example, but then everyone will be informed at the same time.
·2 päivää sittenI still think the stock seems tremendously controlled.·2 päivää sittenIt's probably easier to control the price where they want when there is low trading volume too. Don't forget that. - ·3 päivää sittenReminder: So, not until 19:20 CET can we see/hear anything Immunovia has to tell.
·23.1.News: ”Immunovia (IMMNOV: Nasdaq Stockholm), a diagnostic company in pancreatic cancer, announced today that the company will participate in the investor meeting Aktiesparna Digital Temakväll Life Science. CEO and President Jeff Borcherding will present the company's commercial strategy and launch activities. On January 26, 2026 at 7:20 PM CET, Immunovia will present its strategic plan and operational priorities for the commercialization of the PancreaSure test. In connection with the presentation, the company's CEO and President, Jeff Borcherding, will provide further information on the latest developments in the business, including Immunovia's recently obtained regulatory approval in California which enables the sale of PancreaSure in the state.”
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
64 päivää sitten42 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenIf you are interested in this stock, then watch the interview with Jeff https://www.youtube.com/watch?v=BI2P6nBNMvw&t=740s Anyway, I am strengthened in that this is a mkt interesting case/stock, it feels like one is really on the way to succeed and if one gets the reinbursement during the year according to plan, then I believe that brilliant times await. I bought a bit more·12 t sitten · MuokattuIt's difficult to read Jeff then. But, if one believes him, then it is very positive. Otherwise, there's little new, but he somehow promises something for the annual report. Even if it's only an update on how things are going by the annual report possibly. So that's what people are waiting for. So each and every one of us must interpret how positive this is based on what Jeff shared at the meeting with shareholders. It's probably natural that one doesn't talk about any potential dialogues with partner candidates, if they should have started, or will develop during February. The natural thing is to wait a bit and say it when an agreement is in place. I believe at least things usually work like that in such processes. Also, one should not forget the medicare application in a few months. Maybe that makes partners even more willing?
- ·2 päivää sitten · Muokattuhttps://www.youtube.com/watch?v=BI2P6nBNMvw&t=740s It can be seen as just an opinion. But this is probably the first time I really hear Jeff Boercherdinger say that the test is almost "guaranteed" to provide good enough accuracy. "Proven to be accurate" are the words he uses. "Limited risk around the product" and "very enthusiastic response to the launch". "adopted in Numerous centers already". "I wish to share more information about that in February, when we announce the full year 2025 results" He still maintains that they will apply for Medicare in mid-2026, no change on that point. I am left with the impression from question 1: that Jeff describes medicaid as a poor man's thing without putting that label on it, and that it is medicare that means the most for Immunovia (is that the insured then) !? So he thinks that medicaid, which will take years anyway, has little significance. Question 2 about "investment sentiment picking up": Yes "mood is improving", Acquisitions are somewhat new in the sector and more common in pharma, but it is a signal that can lead to further acquisitions. You haven't seen as many acquisitions in the diagnostics sector, but when it opens up a bit, more interest in Immunovia among investors can be seen. Question 3 about "tariffs": Minimal impact. Small ingredient productions in countries like Germany. Question 4 about whether the California news will provide the first commercial revenues already for Q1 2026: Expects that multiple centers will sign up to use the test. Usual sequence for how things tend to settle: Enter into an agreement with the center, a period of time where they implement the test, and start using it. Then you start to see volume increase. Regarding the revenue part, it will depend on the invoicing we do at the beginning of this year. They start early with invoicing to see if they can get some "reimbursements before we have formal coverage decisions". So he thinks we have to wait and see "how things play out". And that it will have an impact for California as well, as in other states. Question 5 about reverse split of the stock. If the board and larger shareholders now see significant potential for share price increases now that you are on the verge of commercial rollout in the USA? Answer: RS was concluded. Timing signals from shareholders. Bullish on Immunovia, much value in the company. This is poorly reflected in the share price and "in the market capatilization of the company. When you look at the fact that this is a large market with a big unmet need. We have an excisting product. We have had good clinical results behind it and we are getting good feedback from the market. So we do um we do see good opportunity going forward. Slightly unfortunate closing of his eyes when he said the last sentence about "good opportunity" (body language). One might perhaps think that he is sad about what is happening on the streets with the ICE bullies, or? Wouldn't surprise me..
- ·3 päivää sitten · MuokattuI myself believe there is money in a cancer blood test. But today's government in the USA is "very special". So there are probably other markets in the world, one would think? But that happens only after the USA? And there is a certain burn rate now, and how will that go then? https://forum.placera.se/bolag/immunovia Now she is posting extra actively again. At least be a little aware that Elvira on the Placera forum was one of several who hyped the stock between the emission in May 2025 and the next emission autumn 2025. It could be pure naivety. But I myself have lost money on that crowd who go on like that talking about partnerships in the east and in the west. But of course, one day a partnership might come. But no one knows when. One might get news about negotiations, for example, but then everyone will be informed at the same time.·2 päivää sittenI still think the stock seems tremendously controlled.·2 päivää sittenIt's probably easier to control the price where they want when there is low trading volume too. Don't forget that.
- ·3 päivää sittenReminder: So, not until 19:20 CET can we see/hear anything Immunovia has to tell.
- ·23.1.News: ”Immunovia (IMMNOV: Nasdaq Stockholm), a diagnostic company in pancreatic cancer, announced today that the company will participate in the investor meeting Aktiesparna Digital Temakväll Life Science. CEO and President Jeff Borcherding will present the company's commercial strategy and launch activities. On January 26, 2026 at 7:20 PM CET, Immunovia will present its strategic plan and operational priorities for the commercialization of the PancreaSure test. In connection with the presentation, the company's CEO and President, Jeff Borcherding, will provide further information on the latest developments in the business, including Immunovia's recently obtained regulatory approval in California which enables the sale of PancreaSure in the state.”
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
272 586
Myynti
Määrä
162 534
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 19 948 | - | - | ||
| 2 500 | - | - | ||
| 1 687 | - | - | ||
| 10 889 | - | - | ||
| 6 079 | - | - |
Ylin
0,218VWAP
Alin
0,2VaihtoMäärä
1,3 6 527 294
VWAP
Ylin
0,218Alin
0,2VaihtoMäärä
1,3 6 527 294
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 6 527 294 | 6 527 294 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 6 527 294 | 6 527 294 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 24.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 26.11.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 14.5.2025 | |
| 2024 Q4 -tulosraportti | 25.2.2025 | |
| 2024 Q3 -tulosraportti | 27.11.2024 |
2025 Q3 -tulosraportti
64 päivää sitten42 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 24.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 26.11.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 14.5.2025 | |
| 2024 Q4 -tulosraportti | 25.2.2025 | |
| 2024 Q3 -tulosraportti | 27.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenIf you are interested in this stock, then watch the interview with Jeff https://www.youtube.com/watch?v=BI2P6nBNMvw&t=740s Anyway, I am strengthened in that this is a mkt interesting case/stock, it feels like one is really on the way to succeed and if one gets the reinbursement during the year according to plan, then I believe that brilliant times await. I bought a bit more·12 t sitten · MuokattuIt's difficult to read Jeff then. But, if one believes him, then it is very positive. Otherwise, there's little new, but he somehow promises something for the annual report. Even if it's only an update on how things are going by the annual report possibly. So that's what people are waiting for. So each and every one of us must interpret how positive this is based on what Jeff shared at the meeting with shareholders. It's probably natural that one doesn't talk about any potential dialogues with partner candidates, if they should have started, or will develop during February. The natural thing is to wait a bit and say it when an agreement is in place. I believe at least things usually work like that in such processes. Also, one should not forget the medicare application in a few months. Maybe that makes partners even more willing?
- ·2 päivää sitten · Muokattuhttps://www.youtube.com/watch?v=BI2P6nBNMvw&t=740s It can be seen as just an opinion. But this is probably the first time I really hear Jeff Boercherdinger say that the test is almost "guaranteed" to provide good enough accuracy. "Proven to be accurate" are the words he uses. "Limited risk around the product" and "very enthusiastic response to the launch". "adopted in Numerous centers already". "I wish to share more information about that in February, when we announce the full year 2025 results" He still maintains that they will apply for Medicare in mid-2026, no change on that point. I am left with the impression from question 1: that Jeff describes medicaid as a poor man's thing without putting that label on it, and that it is medicare that means the most for Immunovia (is that the insured then) !? So he thinks that medicaid, which will take years anyway, has little significance. Question 2 about "investment sentiment picking up": Yes "mood is improving", Acquisitions are somewhat new in the sector and more common in pharma, but it is a signal that can lead to further acquisitions. You haven't seen as many acquisitions in the diagnostics sector, but when it opens up a bit, more interest in Immunovia among investors can be seen. Question 3 about "tariffs": Minimal impact. Small ingredient productions in countries like Germany. Question 4 about whether the California news will provide the first commercial revenues already for Q1 2026: Expects that multiple centers will sign up to use the test. Usual sequence for how things tend to settle: Enter into an agreement with the center, a period of time where they implement the test, and start using it. Then you start to see volume increase. Regarding the revenue part, it will depend on the invoicing we do at the beginning of this year. They start early with invoicing to see if they can get some "reimbursements before we have formal coverage decisions". So he thinks we have to wait and see "how things play out". And that it will have an impact for California as well, as in other states. Question 5 about reverse split of the stock. If the board and larger shareholders now see significant potential for share price increases now that you are on the verge of commercial rollout in the USA? Answer: RS was concluded. Timing signals from shareholders. Bullish on Immunovia, much value in the company. This is poorly reflected in the share price and "in the market capatilization of the company. When you look at the fact that this is a large market with a big unmet need. We have an excisting product. We have had good clinical results behind it and we are getting good feedback from the market. So we do um we do see good opportunity going forward. Slightly unfortunate closing of his eyes when he said the last sentence about "good opportunity" (body language). One might perhaps think that he is sad about what is happening on the streets with the ICE bullies, or? Wouldn't surprise me..
- ·3 päivää sitten · MuokattuI myself believe there is money in a cancer blood test. But today's government in the USA is "very special". So there are probably other markets in the world, one would think? But that happens only after the USA? And there is a certain burn rate now, and how will that go then? https://forum.placera.se/bolag/immunovia Now she is posting extra actively again. At least be a little aware that Elvira on the Placera forum was one of several who hyped the stock between the emission in May 2025 and the next emission autumn 2025. It could be pure naivety. But I myself have lost money on that crowd who go on like that talking about partnerships in the east and in the west. But of course, one day a partnership might come. But no one knows when. One might get news about negotiations, for example, but then everyone will be informed at the same time.·2 päivää sittenI still think the stock seems tremendously controlled.·2 päivää sittenIt's probably easier to control the price where they want when there is low trading volume too. Don't forget that.
- ·3 päivää sittenReminder: So, not until 19:20 CET can we see/hear anything Immunovia has to tell.
- ·23.1.News: ”Immunovia (IMMNOV: Nasdaq Stockholm), a diagnostic company in pancreatic cancer, announced today that the company will participate in the investor meeting Aktiesparna Digital Temakväll Life Science. CEO and President Jeff Borcherding will present the company's commercial strategy and launch activities. On January 26, 2026 at 7:20 PM CET, Immunovia will present its strategic plan and operational priorities for the commercialization of the PancreaSure test. In connection with the presentation, the company's CEO and President, Jeff Borcherding, will provide further information on the latest developments in the business, including Immunovia's recently obtained regulatory approval in California which enables the sale of PancreaSure in the state.”
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
272 586
Myynti
Määrä
162 534
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 19 948 | - | - | ||
| 2 500 | - | - | ||
| 1 687 | - | - | ||
| 10 889 | - | - | ||
| 6 079 | - | - |
Ylin
0,218VWAP
Alin
0,2VaihtoMäärä
1,3 6 527 294
VWAP
Ylin
0,218Alin
0,2VaihtoMäärä
1,3 6 527 294
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 6 527 294 | 6 527 294 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 6 527 294 | 6 527 294 | 0 | 0 |